Sophia Genetics, an AI-driven precision medicine, has collaborated with The University of Texas MD Anderson Cancer Centre aimed at accelerating data-driven cancer care through advanced analytics and next-generation sequencing technologies.

The partnership brings together AI-powered Sophia DDM Platform with MD Anderson’s clinical and scientific expertise to develop new tools capable of accurately analysing, interpreting and translating complex diagnostic data into clinical practice. As part of the collaboration, the two organisations will launch a series of joint research and development programmes and co-develop an advanced Next-Generation Sequencing (NGS) oncology test.

Built on the DDM Platform’s advanced AI algorithms, the co-developed test is designed to transform complex multimodal data into actionable clinical insights with greater speed and scalability. MD Anderson researchers will leverage the company’s AI technologies to create bioinformatics pipelines that enable rapid interpretation of RNA-sequencing data, supporting more precise diagnosis and treatment decisions for patients with cancer.

Philippe Menu, Chief Product Officer and Chief Medical Officer at Sophia Genetics, said “The collaboration reinforces a shared ambition to push the boundaries of cancer research. Sophia DDM will serve as a unifying analytical layer to enable new discoveries, accelerate breakthroughs in precision oncology and expand patient access to advanced technologies across geographies.”

Commenting on the collaboration, Dr. Donna Hansel, Division Head of Pathology and Laboratory Medicine at MD Anderson, said the rapid evolution of cancer research and the growing availability of health data demand more advanced analytical approaches. She noted that integrating AI-driven analytics will enhance the institution’s ability to interpret complex molecular data and translate high-dimensional information into insights that advance precision oncology.

Beyond test development, both the partners will jointly explore new approaches to characterising tumour evolution in real time, improving the reliability and reproducibility of complex genomic testing, and strengthening the identification of optimal clinical trials and research pathways for individual patients. The multi-layered programme is designed to support next-generation scientific discovery and provide clinicians and researchers with deeper insights into the dynamic nature of cancer.

The collaborative research at MD Anderson will be led by Dr. Shashikant Kulkarni, Deputy Division Head for Molecular Pathology, and Dr. J. Bryan, Assistant Professor in the Division of Pathology and Laboratory Medicine.